Drug-Resistant Fungal Infection Spreads Across 28 States, Posing Ongoing Threat to Vulnerable Patients

Last updated: August 12, 2026

NewsWK — Public health officials across the United States are maintaining heightened vigilance as a stubborn, drug-resistant fungal pathogen continues to afflict patients in long-term care facilities and hospitals nationwide. Federal surveillance data from the Centers for Disease Control and Prevention indicates that more than half of all U.S. states have reported active cases of Candida auris this year, highlighting persistent challenges in healthcare sanitation and infection control.

Through the first seven months of the year, federal health agencies documented 3,544 clinical cases of the fungal yeast across 28 states. While the figure represents a slight decrease compared to the 4,262 clinical infections recorded during the same timeframe last year, medical experts caution that the threat remains serious. The fungus has proven particularly difficult to eradicate due to its unusual capacity to withstand common antifungal medications and persist on medical equipment and surfaces for extended periods.

Why it matters here

For patients, families, and healthcare administrators across the country, the persistent presence of Candida auris directly affects public safety and institutional healthcare management. The pathogen primarily targets individuals who are already experiencing severe health complications or undergoing intensive medical treatments, making nursing homes, rehabilitation centers, and intensive care units the primary battlegrounds against its spread.

The spread of treatment-resistant organisms places an increasing financial and operational strain on the nation’s medical system. Long-term care facilities must invest heavily in rigorous screening procedures, specialized isolation protocols, and specialized cleaning agents to prevent outbreaks. For family members with loved ones residing in eldercare facilities or undergoing complex hospital treatments, understanding these infection control measures is critical to ensuring patient safety and holding facilities accountable for maintaining sanitary standards.

Furthermore, because infected individuals can carry the organism on their skin without showing immediate symptoms—a condition known as colonization—unseen transmission remains a major hazard. As facilities work to balance patient care with strict containment measures, the strain on staff and operational budgets underscores the broader economic and regulatory impacts of hospital-acquired infections.

Regional Impact and Infection Trends

Data compiled through the federal National Notifiable Diseases Surveillance System reveals significant regional variation in the reported incidence of Candida auris. California has registered the highest burden of clinical cases in the nation so far this year, recording 887 verified infections.

Southern states have also observed substantial transmission, accounting for more than 1,400 combined clinical cases. Texas reported the largest volume in the region with 437 cases, followed by Tennessee with 293 diagnoses and Georgia with 193. In the Midwest and Great Lakes region, a cluster of five states—Illinois, Indiana, Michigan, Ohio, and Wisconsin—collectively logged 751 clinical cases.

In the Mountain West, Arizona accounted for the vast majority of regional activity, reporting 171 of the area’s 200 total clinical cases. Meanwhile, Northeastern states reported lower overall numbers, with Pennsylvania documenting 131 clinical cases and New Jersey registering 55.

In addition to active clinical infections, federal tracking identified 3,325 screening detections nationwide as of early August. Screening tests allow health officials to identify colonized individuals who carry the fungus without suffering acute illness. Identifying colonized patients is vital for healthcare staff, as these individuals can unknowingly transmit the organism to other vulnerable patients or contaminate shared medical surfaces.

Clinical Risks and Institutional Challenges

First identified globally in Japan in 2009, Candida auris made its initial documented appearance in the United States in 2016. Between 2019 and 2021, 17 states identified their first local cases, marking a rapid expansion that prompted public health agencies to categorize the organism as an urgent health threat.

Medical authorities emphasize that healthy individuals face minimal risk from the yeast. Instead, the organism poses a grave danger almost exclusively to patients undergoing complex care who have compromised immune systems or severe underlying health conditions. Individuals requiring invasive medical devices—such as central venous catheters, feeding tubes, or mechanical breathing tubes—are particularly susceptible to localized or systemic infections.

Symptoms of a Candida auris infection depend heavily on the site of infection. While superficial skin infections may produce mild localized signs, invasive bloodstream infections can lead to severe illness characterized by high fever and chills that do not respond to standard antibacterial treatments. Because the fungus often resists multiple classes of antifungal drugs, clinicians are frequently left with limited pharmaceutical options to combat active infections.

To curb further spread, health guidelines encourage medical providers to maintain strict surface disinfection, implement proactive patient screening upon admission, and enforce rigorous hygiene among staff and visitors. Maintaining robust oversight and clear standard operating procedures within healthcare institutions remains the primary defense against this evolving medical threat.